Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?

BACKGROUND: Pituitary carcinomas are rare but aggressive and require maximally coordinated multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ), therapeutic options are limited. Immune checkpoint inhibitors (ICI) may be considered for treatment as illustrated in the presen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Endocrinol
Main Authors: Sol, Bastiaan, de Filette, Jeroen M K, Awada, Gil, Raeymaeckers, Steven, Aspeslagh, Sandrine, Andreescu, C E, Neyns, Bart, Velkeniers, Brigitte
Formato: Artigo
Idioma:Inglês
Publicado em: Bioscientifica Ltd 2020
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7707801/
https://ncbi.nlm.nih.gov/pubmed/33112279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EJE-20-0151
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados